Newswise — San Francisco, CA. (April 11, 2014) – For patients undergoing surgery, adding a sedative drug called dexmedetomidine can reduce the necessary doses of other anesthetic drugs, reports a study in the April issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).
Using dexmedetomidine as an adjuvant (additional) agent can not only lower the anesthetic dose but also delay the time until strong pain relievers are needed after surgery, according to the new research by Dr Marc Fischler of Hôpital Foch, Suresnes, France, and colleagues.
Objective Assessment of Adjuvant DexmedetomidineThe study included 60 patients undergoing surgery and anesthesia with two widely used intravenous anesthetic drugs: propofol and remifentanil. Patients were randomly assigned to receive the commonly used sedative drug dexmedetomidine, or an inactive placebo (saline solution).
The doses of propofol and remifentanil required for surgery were compared between groups. The anesthetics were given through an automated "closed-loop" system, which adjusted doses according to a measure of brain activity (the bispectral index) to precisely maintain a target level of anesthesia. This provided an objective measure of depth of anesthesia, minimizing variations in anesthetic dose.
The amounts of anesthetic drugs needed to induce anesthesia were significantly lower in patients receiving dexmedetomidine. The propofol induction dose was 30 percent lower and the remifentanil induction dose 25 percent lower, compared to patients receiving placebo.
The propofol dose needed to maintain the desired level of anesthesia was also about 30 percent lower in the dexmedetomidine group. The maintenance remifentanil dose was unaffected by dexmedetomidine.
Dexmedetomidine Also Helps Control Pain After SurgeryThere was also evidence of an analgesic (pain-relieving) effect of dexmedetomidine. The median time to the first patient request for morphine was four hours after surgery in the dexmedetomidine group, compared to one hour in the placebo group.
There was no difference in recovery time, and no increase in the rate of delayed recovery, among patients receiving dexmedetomidine. Other adverse effects were also similar in the dexmedetomidine and placebo groups.
Dexmedetomidine is commonly used as a sedative for patients receiving mechanical ventilation in the intensive care unit. An alpha-2 adrenergic agonist, dexmedetomidine acts through a different mechanism than propofol or other anesthetics, suggesting that it might be a useful supplement for anesthesia.
Previous studies have that dexmedetomidine can reduce anesthetic and analgesic doses in patients undergoing surgery. However, the new study is the first to show an "anesthetic-sparing" effect using the bispectral index as an objective measure of anesthetic requirements.
The results of this randomized trials show that a relatively low dose of dexmedetomidine can reduce anesthetic dose while also helping to control pain after surgery, without prolonging recovery time. Dr Fischler and coauthors conclude, "Dexmedetomidine is a useful adjuvant that reduces anesthetic requirement and provides postoperative analgesia," Dr Fischler and coauthors conclude.
About Anesthesia & AnalgesiaAnesthesia & Analgesia was founded in 1922 and was issued bi-monthly until 1980, when it became a monthly publication. A&A is the leading journal for anesthesia clinicians and researchers and includes more than 500 articles annually in all areas related to anesthesia and analgesia, such as cardiovascular anesthesiology, patient safety, anesthetic pharmacology, and pain management. The journal is published on behalf of the IARS by Lippincott Williams & Wilkins (LWW), a division of Wolters Kluwer Health.
About the IARSThe International Anesthesia Research Society is a nonpolitical, not-for-profit medical society founded in 1922 to advance and support scientific research and education related to anesthesia, and to improve patient care through basic research. The IARS contributes nearly $1 million annually to fund anesthesia research; provides a forum for anesthesiology leaders to share information and ideas; maintains a worldwide membership of more than 15,000 physicians, physician residents, and others with doctoral degrees, as well as health professionals in anesthesia related practice; sponsors the SmartTots initiative in partnership with the FDA; and publishes the monthly journal Anesthesia & Analgesia in print and online.
About Wolters Kluwer HealthWolters Kluwer Health is a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Serving more than 150 countries worldwide, clinicians rely on Wolters Kluwer Health’s market leading information-enabled tools and software solutions throughout their professional careers from training to research to practice. Major brands include Health Language®, Lexicomp®, Lippincott Williams & Wilkins, Medicom®, Medi-Span®, Medknow, Ovid®, Pharmacy OneSource®, ProVation® Medical and UpToDate®.
Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Wolters Kluwer had 2013 annual revenues of €3.6 billion (US$4.7 billion), employs approximately 19,000 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Follow our official Twitter handle: @WKHealth.